RGEN · Repligen Corporation
$176.93
-1.00% last session
End-of-day data · close of 2026-10-23
Market cap
$11B
Enterprise value
$10B
Trailing P/E
242.4
Forward P/E
65.6
Dividend yield
0.0%
Beta
1.08
Avg volume
1M
Employees
2K
Daily Change %
-1.00%
5 Days Change
1.88%
10 Days Change
1.88%
30 Days Change
-3.15%
60 Days Change
-1.60%
Month to Day Change
0.84%
Year to Day Change
9.06%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RGEN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-19
Latest call per bank · past 12 months
Barclays
Overweight$225
+27.2% vs priceUBS
Buy$225
+27.2% vs priceWells Fargo
Overweight$185
+4.6% vs priceJP Morgan
Overweight$175
-1.1% vs priceHSBC
Buy$150
-15.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Canaccord Genuity | Maintains | Hold | $145 → $180 |
| 2026-10-07 | Barclays | Maintains | Overweight | $175 → $225 |
| 2026-09-09 | UBS | Maintains | Buy | $195 → $225 |
| 2026-07-30 | Wells Fargo | Maintains | Overweight | $180 → $185 |
| 2026-07-29 | JP Morgan | Maintains | Overweight | $165 → $175 |
| 2026-07-07 | Benchmark | Upgrade | Hold → Buy | $0.00 → $185 |
| 2026-07-06 | Evercore ISI Group | Maintains | Outperform | $150 → $160 |
| 2026-06-03 | HSBC | Maintains | Buy | $170 → $150 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 50 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 0.1% below the 50-day MA ($177.10).
- bullish: Price vs 200-day MA: Trading 22.5% above the 200-day MA ($144.39).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.28) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($102.87) and high ($194.57).
RGEN Price Chart
Loading chart for RGEN…
Fundamentals
About Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
More in Medical Instruments & Supplies
ISRG
Intuitive Surgical, Inc.
$160B -21.6% YTD
BDX
Becton, Dickinson and Company
$54B 33.9% YTD
MDLN
Medline Inc.
$46B -17.0% YTD
RMD
ResMed Inc.
$36B 5.9% YTD
ALC
Alcon Inc.
$34B -9.9% YTD
WST
West Pharmaceutical Services, I
$28B 43.5% YTD
SOLV
Solventum Corporation
$15B 10.4% YTD
BAX
Baxter International Inc.
$13B 34.4% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.